U.S. INDUSTRY &
WORKFORCE NEWS

REAL STORIES. REAL WORKERS. REAL STRENGTH.

Monday, November 16, 2026

FDA Expands U.S. Label for ImmunityBio’s Anktiva Bladder Cancer Drug

The FDA has expanded the approved use of ImmunityBio's Anktiva, in combination with BCG, to include adults with BCG-unresponsive high-grade papillary-only non-muscle-invasive bladder cancer, broadening treatment options for this patient group.

The U.S. Food and Drug Administration (FDA) has announced an expansion of the approved indication for ImmunityBio’s Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gue9rin (BCG) for the treatment of certain bladder cancer patients. The new label now includes adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer (NMIBC), a form of cancer that has not invaded the bladder muscle but has failed BCG treatment.

Prior to this expansion, Anktiva was approved in 2024 for use in combination with BCG for patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors. The FDA described the expanded indication as the first specifically approved treatment option for the papillary-only patient population, addressing a significant unmet need.

ImmunityBios Anktiva is an immunotherapy designed to activate the immune system to attack bladder cancer cells, administered alongside the standard BCG therapy. This expansion enables broader patient access to this treatment, potentially improving outcomes for those with this form of bladder cancer who have limited options after BCG failure.

The FDAs decision reflects growing recognition of the importance of targeted immunotherapies in managing non-muscle-invasive bladder cancer and the need for therapies approved specifically for subtypes of this disease.

With bladder cancer one of the most common cancers in the U.S., and NMIBC accounting for the majority of cases, the expanded approval could affect a substantial patient population, providing an important new treatment pathway.

Search American Industries News